Eli Lilly close to buying gene-editing biotech Verve Therapeutics
Drugmaker nears $1.3bn deal in search for experimental medicines
Related reading
Novartis weighs deal for biotech Avidity to boost drug pipeline
Shares in rare disease biotech surge 26% following approach by Swiss group
Eli Lilly becomes first pharma group to join $1tn club
Shares have soared more than 40% this year over strong demand for weight-loss and diabetes drugs
Eli Lilly pushes for NHS drug price increases in return for its UK investment
US pharmaceutical group ‘optimistic’ about reaching deal with British government
Eli Lilly not yet ready to unfreeze UK investments, says pharma boss
US drugmaker wants changes to types of drugs approved in Britain
How AI can recode the difficult process of drug discovery
Research organisations are banking on technology to help improve the odds of approval
Big Pharma is falling out of love with Britain
Life sciences should be a natural place to look for growth